U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H24F2N6O
Molecular Weight 366.4095
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GOSOGLIPTIN

SMILES

c1cnc(nc1)N2CCN(CC2)[C@@]3([H])C[C@@]([H])(C(=O)N4CCC(C4)(F)F)NC3

InChI

InChIKey=QWEWGXUTRTXFRF-KBPBESRZSA-N
InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1

HIDE SMILES / InChI
Molecular Formula C17H24F2N6O
Molecular Weight 366.4095
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Gosogliptin (PF-734200) is a compound developed for treatment of type II diabetes and has been approved for use in Russia. It is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, with hypoglycemic activity. The drug is safe and well tolerated at all doses tested when added to metformin (a diabetes drug), and safely and effectively lowered HbA (1c) in subjects receiving metformin. A phase 3 study to study the safety and efficacy of gosogliptin has been completed. Gosogliptin has also been studied as potential drug for the treatment of renal insufficiency.

Originator

Approval Year

Unknown
109281
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
 13.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
2009 Apr 1
The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.
2011 Jul
Patents

Patents

20050256310
1
JP2007537231A
1
JP2011529945A
15
JP2012500190A
16
JP4227660B2
1
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:34:58 UTC 2021
Edited
by admin
on Sat Jun 26 04:34:58 UTC 2021
Record UNII
GI718UO477
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GOSOGLIPTIN
INN   USAN  
USAN   INN  
Official Name English
(3,3-DIFLUOROPYRROLIDIN-1-YL)((2S,4S)-4-(4-(PYRIMIDIN-2-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YL)METHANONE
Systematic Name English
PF-734200
Code English
GOSOGLIPTIN [INN]
Common Name English
GOSOGLIPTIN [USAN]
Common Name English
METHANONE, (3,3-DIFLUORO-1-PYRROLIDINYL)((2S,4S)-4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)-2-PYRROLIDINYL)-
Systematic Name English
PF-734,200
Code English
PF-00734200
Code English
GOSOGLIPTIN [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98086
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
Code System Code Type Description
FDA UNII
GI718UO477
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
INN
9148
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
CAS
869490-23-3
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL515387
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
PUBCHEM
11516136
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
DRUG BANK
DB08382
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
NCI_THESAURUS
C90616
Created by admin on Sat Jun 26 04:34:59 UTC 2021 , Edited by admin on Sat Jun 26 04:34:59 UTC 2021
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of GOSOGLIPTIN
EXCRETED UNCHANGED
FECAL
Structure of GOSOGLIPTIN
EXCRETED UNCHANGED
URINE
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of METHANONE, (3,3-DIFLUORO-1-PYRROLIDINYL)((2S,4S)-4-(4-(5-HYDROXY-2-PYRIMIDINYL)-1-PIPERAZINYL)-2-PYRROLIDINYL)-
METABOLITE -> PARENT
FECAL
Structure of METHANONE, (3,3-DIFLUORO-1-PYRROLIDINYL)((2S,4S)-4-(4-(5-HYDROXY-2-PYRIMIDINYL)-1-PIPERAZINYL)-2-PYRROLIDINYL)-
METABOLITE -> PARENT
URINE
Structure of METHANONE, (3,3-DIFLUORO-1-PYRROLIDINYL)((2S,4S)-4-(4-(5-HYDROXY-2-PYRIMIDINYL)-1-PIPERAZINYL)-2-PYRROLIDINYL)-
METABOLITE -> PARENT
PLASMA
Structure of L-PROLINE, 4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)-, (4S)-
METABOLITE -> PARENT
FECAL
Structure of .BETA.-D-GLUCOPYRANURONIC ACID, 1-((2S,4S)-2-((3,3-DIFLUORO-1-PYRROLIDINYL)CARBONYL)-4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)-1-PYRROLIDINECARBOXYLATE)
METABOLITE -> PARENT
PLASMA
Structure of 1-PIPERAZINECARBOXIMIDAMIDE, 4-((3S,5S)-5-((3,3-DIFLUORO-1-PYRROLIDINYL)CARBONYL)-3-PYRROLIDINYL)-
METABOLITE -> PARENT
FECAL
Structure of (3,3-DIFLUOROPYRROLIDIN-1-YL)-((2S,4S)-4-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)-1-((2R,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-2-YL)PYRROLIDIN-2-YL)METHANONE
METABOLITE -> PARENT
URINE
Structure of L-PROLINE, 4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)-, (4S)-
METABOLITE -> PARENT
URINE
Structure of .BETA.-D-GLUCOPYRANURONIC ACID, 1-((2S,4S)-2-((3,3-DIFLUORO-1-PYRROLIDINYL)CARBONYL)-4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)-1-PYRROLIDINECARBOXYLATE)
METABOLITE -> PARENT
Metabolite M9 could not be chromatographically resolved in human urine.
URINE
Structure of 1-PIPERAZINECARBOXIMIDAMIDE, 4-((3S,5S)-5-((3,3-DIFLUORO-1-PYRROLIDINYL)CARBONYL)-1-FORMYL-3-PYRROLIDINYL)-
METABOLITE -> PARENT
URINE
Structure of 1-PYRROLIDINECARBOXALDEHYDE, 2-((3,3-DIFLUORO-1-PYRROLIDINYL)CARBONYL)-4-(4-(5-HYDROXY-2-PYRIMIDINYL)-1-PIPERAZINYL)-, (2S,4S)-
METABOLITE -> PARENT
URINE
Structure of 1-PYRROLIDINECARBOXAMIDE, 2-((3,3-DIFLUORO-1-PYRROLIDINYL)CARBONYL)-4-(4-(5-HYDROXY-2-PYRIMIDINYL)-1-PIPERAZINYL)-, (2S,4S)-
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of GOSOGLIPTIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

IN HEALTHY MALE VOLUNTEERS

Biological Half-life PHARMACOKINETIC IN HEALTHY MALE VOLUNTEERS

SINGLE DOSE

ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966